Autolus Therapeutics (AUTL) Short-term Investments (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Short-term Investments for 8 consecutive years, with $196.6 million the latest figure, recorded in Q4 2025.

• Quarterly Short-term Investments fell 45.49% year-over-year to $196.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $196.6 million (down 45.49% YoY) and the FY2025 annual result came in at $196.6 million, down 45.49% from the prior year.
• Short-term Investments fell to $196.6 million in Q4 2025 per AUTL's latest filing, from $281.3 million in the prior quarter.
• Over the last five years, Short-term Investments for AUTL reached as high as $420.8 million in Q1 2025 and fell as low as $210000.0 in Q2 2021.
• A 5-year average of $79.9 million and a median of $601500.0 in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2021 — Short-term Investments sank 73.28% — and 2024, when it jumped 46797.66%.
• Year by year, Short-term Investments stood at $338000.0 in 2021, then declined by 3.85% to $325000.0 in 2022, then soared by 136.62% to $769000.0 in 2023, then soared by 46797.66% to $360.6 million in 2024, then slumped by 45.49% to $196.6 million in 2025.
• According to Business Quant data, Short-term Investments over the past three periods registered $196.6 million, $281.3 million, and $330.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.